Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report
作者： PING ZHAN , HAIYAN XIE , LI-KE YU
DOI: 10.3892/OL.2015.2953
关键词: Oncology 、 Pleural effusion 、 Thymic carcinoma 、 Pathology 、 Chemotherapy 、 Molecular medicine 、 Cancer 、 Lung 、 Internal medicine 、 Radiation therapy 、 Nedaplatin 、 Medicine
摘要: Metastatic thymic carcinoma is an aggressive cancer that usually responds poorly to multimodal therapies. Although surgical resection the preferred treatment for patients with advanced or metastatic disease, clinical prognosis typically poor. The present study describes a 63-year-old patient who underwent range of antitumor treatments, including resection, post-operative radiotherapy and chemotherapy several drugs, but ultimately responded nab-paclitaxel (nab-P) nedaplatin. Subsequent six cycles nab-P nedaplatin, lung peritoneal metastases decreased in size pleural effusion was reduced. To best our knowledge, this first describe response chemotherapy.
sci-hub.se 参考文章(19)
Kazuaki Takabe, Omar M. Rashid, Anthony D. Cassano, Thymic neoplasm: a rare disease with a complex clinical presentation. Journal of Thoracic Disease. ,vol. 5, pp. 173- 183 ,(2013) , 10.3978/J.ISSN.2072-1439.2013.01.12
A MASAOKA, Y YAMAKAWA, H NIWA, I FUKAI, Y SAITO, S TOKUDOME, K NAKAHARA, Y FUJII, Thymectomy and malignancy. European Journal of Cardio-Thoracic Surgery. ,vol. 8, pp. 251- 253 ,(1994) , 10.1016/1010-7940(94)90155-4
P Ströbel, R Bargou, A Wolff, D Spitzer, C Manegold, A Dimitrakopoulou-Strauss, L Strauss, C Sauer, F Mayer, P Hohenberger, A Marx, Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. British Journal of Cancer. ,vol. 103, pp. 196- 200 ,(2010) , 10.1038/SJ.BJC.6605740
Kazuya Kondo, Yasumasa Monden, Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan The Annals of Thoracic Surgery. ,vol. 76, pp. 878- 884 ,(2003) , 10.1016/S0003-4975(03)00555-1
Giancarlo Bisagni, Giulio Rossi, Alberto Cavazza, Giuliana Sartori, Giorgio Gardini, Corrado Boni, Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma Journal of Thoracic Oncology. ,vol. 4, pp. 773- 775 ,(2009) , 10.1097/JTO.0B013E3181A52E25
Makoto Suzuki, Hong Chen, Hisayuki Shigematsu, Soichiro Ando, Tomohiko Iida, Takahiro Nakajima, Takehiko Fujisawa, Hideki Kimura, Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncology Reports. ,vol. 14, pp. 1621- 1624 ,(2005) , 10.3892/OR.14.6.1621
Nicolas Girard, Françoise Mornex, Paul Van Houtte, Jean-François Cordier, Paul van Schil, Thymoma: A Focus on Current Therapeutic Management Journal of Thoracic Oncology. ,vol. 4, pp. 119- 126 ,(2009) , 10.1097/JTO.0B013E31818E105C
Erin R. Gardner, William L. Dahut, Charity D. Scripture, Jacquin Jones, Jeanny B. Aragon-Ching, Neil Desai, Michael J. Hawkins, Alex Sparreboom, William D. Figg, Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel Clinical Cancer Research. ,vol. 14, pp. 4200- 4205 ,(2008) , 10.1158/1078-0432.CCR-07-4592
Nicolas Girard, Ronglai Shen, Tianhua Guo, Maureen F. Zakowski, Adriana Heguy, Gregory J. Riely, James Huang, Christopher Lau, Alex E. Lash, Marc Ladanyi, Agnes Viale, Cristina R. Antonescu, William D. Travis, Valerie W. Rusch, Mark G. Kris, William Pao, Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clinical Cancer Research. ,vol. 15, pp. 6790- 6799 ,(2009) , 10.1158/1078-0432.CCR-09-0644
Eric A. Engels, Epidemiology of Thymoma and Associated Malignancies Journal of Thoracic Oncology. ,vol. 5, pp. S260- S265 ,(2010) , 10.1097/JTO.0B013E3181F1F62D